| Literature DB >> 27807284 |
Calliope A Dendrou1, Adrian Cortes1,2, Lydia Shipman1, Hayley G Evans1, Kathrine E Attfield3, Luke Jostins2, Thomas Barber1, Gurman Kaur3, Subita Balaram Kuttikkatte3, Oliver A Leach1, Christiane Desel1, Soren L Faergeman1,4, Jane Cheeseman5, Matt J Neville5,6, Stephen Sawcer7, Alastair Compston7, Adam R Johnson8, Christine Everett8, John I Bell9, Fredrik Karpe5,6, Mark Ultsch8, Charles Eigenbrot8, Gil McVean2, Lars Fugger10,3,4.
Abstract
Thousands of genetic variants have been identified, which contribute to the development of complex diseases, but determining how to elucidate their biological consequences for translation into clinical benefit is challenging. Conflicting evidence regarding the functional impact of genetic variants in the tyrosine kinase 2 (TYK2) gene, which is differentially associated with common autoimmune diseases, currently obscures the potential of TYK2 as a therapeutic target. We aimed to resolve this conflict by performing genetic meta-analysis across disorders; subsequent molecular, cellular, in vivo, and structural functional follow-up; and epidemiological studies. Our data revealed a protective homozygous effect that defined a signaling optimum between autoimmunity and immunodeficiency and identified TYK2 as a potential drug target for certain common autoimmune disorders.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27807284 PMCID: PMC5737835 DOI: 10.1126/scitranslmed.aag1974
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956